Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.40 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 3/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13009740 | 0.92 | ENPP1 (0.41) | ENPP1OPRK1DHODHPRMT5WDR77 | |
| SCHEMBL13009733 | 0.90 | ENPP1 (0.40) | ENPP1OPRK1DHODHPRMT5WDR77 | |
| SCHEMBL13009737 | 0.81 | OPRK1 (0.48) | ENPP1OPRK1DGAT1 | |
| SCHEMBL3545445 | 0.81 | DHODH (0.39) | ENPP1OPRK1DHODHPRMT5WDR77 | |
| SCHEMBL3537299 | 0.81 | DGAT1 (0.49) | DGAT1DEGS1 | |
| SCHEMBL13009345 | 0.78 | DGAT1 (0.51) | DGAT1 | |
| SCHEMBL13009734 | 0.77 | OPRK1 (0.52) | ENPP1OPRK1MAPK1 | |
| SCHEMBL3549423 | 0.75 | KDM4E (0.46) | OPRK1DHODHMALT1MAPK1 | |
| SCHEMBL3539277 | 0.73 | KDM4E (0.45) | OPRK1MALT1MAPK1 | |
| SCHEMBL3542120 | 0.72 | OPRK1 (0.40) | OPRK1DHODHMALT1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | ENPP1 2244/4885OPRK1 1124/4885DHODH 80/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | ENPP1 2379/4885OPRK1 1053/4885DHODH 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.